Your browser is no longer supported. Please, upgrade your browser.
ARGX argenx SE daily Stock Chart
ARGX [NASD]
argenx SE
Index- P/E- EPS (ttm)-1.73 Insider Own- Shs Outstand42.72M Perf Week40.61%
Market Cap9.37B Forward P/E- EPS next Y-8.45 Insider Trans- Shs Float41.63M Perf Month47.04%
Income- PEG- EPS next Q-1.73 Inst Own56.49% Short Float2.07% Perf Quarter55.11%
Sales- P/S- EPS this Y-69.00% Inst Trans- Short Ratio4.87 Perf Half Y49.68%
Book/sh11.95 P/B18.35 EPS next Y-6.80% ROA- Target Price184.52 Perf Year71.25%
Cash/sh- P/C- EPS next 5Y- ROE- 52W Range103.75 - 222.67 Perf YTD36.62%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-1.51% Beta-
Dividend %- Quick Ratio- Sales past 5Y- Gross Margin- 52W Low111.37% ATR9.56
Employees186 Current Ratio- Sales Q/Q-41.50% Oper. Margin- RSI (14)84.31 Volatility5.98% 3.83%
OptionableYes Debt/Eq- EPS Q/Q- Profit Margin- Rel Volume1.51 Prev Close211.68
ShortableYes LT Debt/Eq- EarningsMay 14 BMO Payout- Avg Volume177.08K Price219.30
Recom1.80 SMA2036.38% SMA5050.24% SMA20055.83% Volume266,515 Change3.60%
Feb-10-20Initiated BofA/Merrill Buy
Nov-05-19Initiated Credit Suisse Neutral $137
Oct-31-19Upgrade William Blair Mkt Perform → Outperform
Oct-22-19Initiated JP Morgan Overweight $167
Sep-27-19Initiated Wells Fargo Market Perform
Sep-16-19Resumed Cowen Outperform
Jun-28-19Initiated Robert W. Baird Outperform
Jan-18-19Resumed SunTrust Buy
Jan-04-19Initiated Morgan Stanley Overweight
Dec-17-18Initiated Goldman Buy
Dec-14-18Initiated Wolfe Research Outperform
Jun-29-18Initiated Nomura Buy $161
Apr-09-18Initiated SunTrust Buy $125
Jan-29-18Reiterated JMP Securities Mkt Outperform $74 → $87
May-29-20 01:00AM  argenx announces full exercise of underwriters option to purchase additional ADSs GlobeNewswire
May-28-20 12:15AM  argenx raises $750 million in gross proceeds in a global offering GlobeNewswire
May-27-20 10:08AM  Biotech Stock Roundup: REGN's Stake Buyback, INO, NVAX's Coronavirus Updates & More Zacks
10:08AM  argenx Up on Positive Data from Pivotal Efgartigimod Study Zacks
07:25AM  The Daily Biotech Pulse: Cumberland's Positive Anti-Bacterial Readout, FDA Nods For Bristol-Myers, Astellas Benzinga
May-26-20 04:01PM  argenx announces launch of proposed global offering GlobeNewswire +34.29%
12:57PM  Here's Why argenx Stock Is Soaring Today Motley Fool
01:00AM  argenx Announces Positive Topline Results from Phase 3 ADAPT Trial of Efgartigimod in Patients with Generalized Myasthenia Gravis GlobeNewswire
May-14-20 03:30PM  argenx SE (ARGX) Q1 2020 Earnings Call Transcript Motley Fool
01:00AM  argenx reports first quarter 2020 financial results and provides business update GlobeNewswire
May-12-20 09:52AM  Halozyme (HALO) Q1 Earnings and Revenues Miss Estimates Zacks
May-11-20 05:22AM  The argenx (EBR:ARGX) Share Price Gained 1374% And Shareholders Are Jubilant Simply Wall St.
May-08-20 11:46AM  7 Strong Buy Healthcare Stocks to Buy Now InvestorPlace
Mar-22-20 10:18PM  argenx SE (ARGX): Hedge Funds In Wait-and-See Mode Insider Monkey
Feb-27-20 08:09AM  Top Ranked Momentum Stocks to Buy for February 27th Zacks
01:00AM  argenx reports full year 2019 financial results and provides fourth quarter business update GlobeNewswire
Feb-26-20 08:57AM  Why Earnings Season Could Be Great for argenx (ARGX)? Zacks
Feb-09-20 03:01AM  Our Take On argenx SE's (EBR:ARGX) CEO Salary Simply Wall St.
Jan-07-20 08:40AM  These 3 Healthcare Stocks Are Set to Soar in 2020, Says Cowen TipRanks
Dec-29-19 09:40PM  Week Ahead In Biotech: PDUFA Date Ahead For Astra Zeneca, Merck's Lynparza, Pending Clinical Readouts In Focus Benzinga
Dec-07-19 08:02AM  Hedge Funds Are Warming Up To argenx SE (ARGX) Insider Monkey
Nov-22-19 03:22PM  3 Strong Buy Biotech Stocks to Watch After Stifel Healthcare Conference TipRanks
Nov-12-19 04:00PM  argenx announces closing of global offering GlobeNewswire
Nov-10-19 02:52AM  If You Had Bought argenx (EBR:ARGX) Stock Five Years Ago, You Could Pocket A 1527% Gain Today Simply Wall St.
Nov-08-19 01:00AM  argenx announces full exercise of underwriters option to purchase additional ADSs GlobeNewswire
Nov-06-19 10:45PM  argenx raises $484 million in gross proceeds in a global offering GlobeNewswire
Oct-24-19 01:00AM  argenx reports third quarter 2019 financial results and provides business update GlobeNewswire
Oct-14-19 10:14PM  Hedge Funds Are Dumping argenx SE (ARGX) Insider Monkey
Sep-25-19 03:34AM  Read This Before Buying argenx SE (EBR:ARGX) Shares Simply Wall St.
Sep-03-19 01:00AM  argenx to Present at Morgan Stanley 17th Annual Global Healthcare Conference GlobeNewswire
Aug-07-19 04:43AM  Is argenx SE's (EBR:ARGX) CEO Paid Enough Relative To Peers? Simply Wall St.
Aug-06-19 01:00AM  argenx to Present at 2019 Wedbush PacGrow Healthcare Conference GlobeNewswire
Aug-01-19 01:00AM  argenx reports half year 2019 financial results and second quarter business update GlobeNewswire
Jul-25-19 01:00AM  argenx to report half year 2019 financial results and second quarter business update on August 1, 2019 GlobeNewswire
Jul-08-19 10:00AM  Here's Why Momentum Investors Will Love ARGENX SE-ADR (ARGX) Zacks
Jun-20-19 01:35PM  Heres What Hedge Funds Think About argenx SE (ARGX) Insider Monkey
Jun-05-19 08:37AM  How Does argenx SE (EBR:ARGX) Affect Your Portfolio Volatility? Simply Wall St.
May-22-19 07:34AM  The Daily Biotech Pulse: Tocagen Tumbles, OncoSec Offering, Novartis Asthma Combo Drug Study Benzinga
01:00AM  argenx announces pipeline expansion and argenx 2021 vision to build integrated immunology company at 2019 R&D Day GlobeNewswire
May-02-19 06:43PM  Eaton Vance Worldwide Health Sciences Fund Buys 5 New Stocks GuruFocus.com
Apr-25-19 02:38PM  Did Hedge Funds Drop The Ball On argenx SE (ARGX) ? Insider Monkey
Apr-13-19 07:41AM  Want an insiders way to play IPOs? This fund has had outsize success with its strategy MarketWatch
Apr-03-19 05:35AM  Has argenx SE (EBR:ARGX) Got Enough Cash? Simply Wall St.
Feb-28-19 07:00AM  argenx SE ADR to Host Earnings Call ACCESSWIRE
Feb-04-19 01:00AM  argenx and Halozyme Enter Global Collaboration and License Agreement for ENHANZE® Technology PR Newswire
01:00AM  argenx and Halozyme enter global collaboration and license agreement for ENHANZE® technology GlobeNewswire
Jan-23-19 07:55AM  Today's Research Reports on Trending Tickers: Editas Medicine and argenx ACCESSWIRE
Jan-22-19 01:52AM  Who Has Been Selling argenx SE (EBR:ARGX) Shares? Simply Wall St.
Dec-26-18 02:22PM  6 Valuable Pipeline Drugs With Upcoming Catalysts Benzinga +5.38%
Dec-03-18 04:09AM  Dutch firm argenx, J&J affiliate to collaborate on cancer therapy Reuters +13.49%
01:00AM  argenx Provides Detailed Data from Phase 2 Clinical Trial of Efgartigimod in Immune Thrombocytopenia and Phase 1/2 Clinical Trial of Cusatuzumab in Acute Myeloid Leukemia GlobeNewswire
01:00AM  argenx enters exclusive global collaboration and license agreement with Cilag GmbH International, an affiliate of Janssen, for cusatuzumab (ARGX-110) GlobeNewswire
Nov-01-18 09:15AM  argenx announces new cusatuzumab (ARGX-110) AML data in abstracts published in connection with 60th American Society of Hematology Annual Meeting and Exposition GlobeNewswire +20.05%
Oct-25-18 02:04AM  Is argenx SEs (EBR:ARGX) Liquidity Good Enough? Simply Wall St.
01:00AM  argenx reports third quarter 2018 financial results and provides business update GlobeNewswire
Oct-09-18 01:00AM  argenx awarded 2.6 million VLAIO grant to explore new applications of ABDEG technology GlobeNewswire
Sep-21-18 04:01PM  argenx announces closing of U.S. public offering for gross proceeds of approximately $300.6 million GlobeNewswire
Sep-18-18 08:46PM  argenx raises approximately $300.6 million in gross proceeds in a U.S. public offering GlobeNewswire -6.90%
08:44AM  The Daily Biotech Pulse: Morphosys Expands Collaboration, Osiris Announces Product Launch, Argenx To Offer Shares Benzinga
Sep-17-18 04:21PM  argenx announces launch of proposed public offering in the United States GlobeNewswire
01:01AM  argenx reports positive topline results from Phase 2 proof-of-concept trial of efgartigimod in primary immune thrombocytopenia GlobeNewswire
Sep-06-18 01:01AM  argenx doses first patient in global Phase 3 registration trial of efgartigimod for the treatment of generalized myasthenia gravis GlobeNewswire
Aug-29-18 01:01AM  argenx receives feedback from Japan's PMDA on Phase 3 clinical trial and regulatory pathway for efgartigimod in generalized myasthenia gravis GlobeNewswire
Aug-22-18 10:50AM  Argenx Shares Up After AbbVie Exercises Option To License Immuno-Oncology Drug Benzinga
03:47AM  AbbVie doubles down on cancer project with biotech group Argenx Reuters
02:01AM  argenx announces that AbbVie has exercised its exclusive option to license ARGX-115, a novel immuno-oncology antibody GlobeNewswire
Aug-09-18 04:06PM  argenx to Present at 2018 Wedbush PacGrow Healthcare Conference GlobeNewswire
Aug-02-18 01:01AM  argenx reports second quarter business update and half-year 2018 financial results GlobeNewswire
Jul-26-18 01:06AM  argenx to host conference call & webcast to report second quarter business update and half year 2018 financial results on August 2, 2018 GlobeNewswire
Jul-24-18 04:01PM  argenx announces publication of full data from Phase 1 healthy volunteer study of efgartigimod in Journal of Clinical Investigation GlobeNewswire
Jul-17-18 01:01AM  argenx receives milestone payment from strategic collaboration with Shire GlobeNewswire
Jun-28-18 01:01AM  argenx receives second preclinical milestone payment under its development agreement with AbbVie GlobeNewswire
01:00AM  argenx receives second preclinical milestone payment under its development agreement with AbbVie GlobeNewswire
Jun-20-18 01:02AM  argenx reports interim data from first cohort of Phase 2 proof-of-concept clinical trial of efgartigimod for the treatment of pemphigus vulgaris GlobeNewswire
Jun-14-18 01:01AM  argenx announces data from Phase 1 study of efgartigimod (ARGX-113) subcutaneous formulation demonstrating comparable characteristics to intravenous formulation GlobeNewswire
Jun-12-18 01:01AM  argenx to host KOL breakfast symposium on immune thrombocytopenia on June 19, 2018 GlobeNewswire
Jun-06-18 01:02AM  argenx receives feedback from FDA in end-of-phase 2 meeting for efgartigimod in myasthenia gravis GlobeNewswire
Jun-05-18 04:01PM  argenx selected for BEL 20 Index GlobeNewswire
May-28-18 05:51AM  Is argenx SE (EBR:ARGX) A Financially Strong Company? Simply Wall St.
May-17-18 01:01AM  argenx to Present at Upcoming Investor Conferences GlobeNewswire
May-09-18 01:01AM  argenx reports first quarter 2018 financial results and provides business update GlobeNewswire
May-08-18 04:31AM  argenx announces results of Annual General Meeting of Shareholders GlobeNewswire
May-01-18 10:27AM  Five Stocks To Buy According To Top Biotech-Focused Funds Insider Monkey
Apr-26-18 07:25AM  Blog Exposure - Argenx to Present Complete Data from Phase-2 Clinical Trial of Efgartigimod (ARGX-113) at AAN Annual Meeting ACCESSWIRE
Apr-24-18 01:01AM  argenx to present complete data from the Phase 2 proof-of-concept trial of efgartigimod (ARGX-113) in generalized myasthenia gravis at American Academy of Neurology (AAN) Annual Meeting GlobeNewswire
01:01AM  argenx to present complete data from the Phase 2 proof-of-concept trial of efgartigimod (ARGX-113) in generalized myasthenia gravis at American Academy of Neurology (AAN) Annual Meeting GlobeNewswire
Apr-12-18 01:01AM  argenx to receive third preclinical milestone payment from collaboration with LEO Pharma - Milestone associated with CTA approval for ARGX-112 GlobeNewswire +5.82%
Apr-09-18 01:01AM  argenx appoints Keith Woods as Chief Operating Officer GlobeNewswire +6.73%
Apr-03-18 01:01AM  argenx to present complete data from the Phase 2 clinical trial of efgartigimod (ARGX-113) in myasthenia gravis at the American Academy of Neurology Annual Meeting GlobeNewswire
Apr-02-18 09:22AM  3 Biotech Stocks Hitting New Highs Investopedia
Mar-26-18 09:57PM  argenx announces Annual General Meeting of Shareholders on May 8, 2018 GlobeNewswire
09:00AM  argenx announces orphan drug designation for ARGX-113 for the treatment of myasthenia gravis in Europe GlobeNewswire
08:28AM  Benzinga Pro's 5 Stocks To Watch Today Benzinga
01:01AM  argenx announces orphan drug designation for ARGX-113 for the treatment of myasthenia gravis in Europe GlobeNewswire
Mar-22-18 02:01AM  argenx announces expansion of its pipeline with addition of complement-targeted ARGX-117 for treatment of severe autoimmune diseases GlobeNewswire
Mar-16-18 02:01AM  argenx awarded 2.5 million VLAIO grant to identify novel therapeutic antibodies GlobeNewswire
Mar-12-18 02:04AM  argenx SEs (EBR:ARGX) Profit Outlook Simply Wall St.
Mar-06-18 01:01AM  argenx to Present at Cowen & Company 38th Annual Health Care Conference GlobeNewswire
Mar-01-18 01:01AM  argenx reports fourth quarter business update and full year 2017 financial results GlobeNewswire +6.97%
01:01AM  argenx reports fourth quarter business update and full year 2017 financial results GlobeNewswire
argenx SE, a clinical-stage biotechnology company, focuses on developing antibody-based therapies for the treatment of autoimmune diseases, hematology, and cancer. It is developing its lead product candidate, efgartigimod, for the treatment of patients with myasthenia gravis in Phase 3; immune thrombocytopenia in Phase 3; pemphigus vulgaris in Phase 2; chronic inflammatory demyelinating polyneuropathy in Phase 2; and ENHANZE SC in pre-clinical stages. The company is also developing cusatuzumab in Phase 2 clinical stage in hematological cancer indications; and preclinical products, including ARGX-117 with therapeutic potential in both orphan and large autoimmune inflammatory diseases in and ARGX-118 for airway inflammation. Its partnered product candidates include ARGX-112 for treating skin inflammation and ARGX-115 for cancer immunotherapy, which are in Phase 1 clinical stages; and ARGX-116 for the treatment of dyslipidemia and ARGX-114 for treating fibrosis, which are in preclinical stage. The company has strategic partnership with AbbVie S.À.R.L. and LEO Pharma A/S; and collaboration agreement with Cilag GmbH International, Staten Biotechnology B.V., and Shire International GmbH. argenx SE was founded in 2008 and is based in Breda, the Netherlands.